Oppenheimer analyst Christopher Marai was out pounding the table on Sarepta Therapeutics Inc (NASDAQ:SRPT) Monday, reiterating an Outperform rating and price target of $60, which …
In a research report published Wednesday, Oppenheimer’s healthcare analyst Christopher Marai reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ:SRPT), while raising the price target …
Oppenheimer analyst Christopher Marai came out today with a few insights on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), after attending the FDA advisory meeting for Kyndrisa, the company’s treatment for Duchenne …
In a research report released Monday, Oppenheimer analyst Christopher Marai reiterated an Outperform rating on shares of Sarepta Therapeutics Inc (NASDAQ :SRPT), with a price …
Oppenheimer’s healthcare analyst Christopher Marai came out with a research report on CytRx Corporation (NASDAQ:CYTR), reiterating an Outperform rating and a $10 price …
Oppenheimer analyst Christopher Marai offered some of his opinions on Celldex Therapeutics, Inc. (NASDAQ:CLDX) following a DSMB recommendation to continue the ongoing P3 trial (ACT-IV) …
Oppenheimer analyst Christopher Marai came out with a research report on Sarepta Therapeutics Inc (NASDAQ:SRPT) after the company completed its rolling NDA for eteplirsen, a trial …
In a research report released Sunday, Oppenheimer analyst Christopher Marai maintained an Outperform rating on Uniqure NV (NASDAQ:QURE) with a price target of $47, …
Oppenheimer analyst Christopher Marai came out with some insights on Incyte Corporation (NASDAQ:INCY) after detailed data from the baricitinib BUILD and BEACON P3 studies was …
Oppenheimer analyst Christopher Marai initiated coverage on Agenus Inc (NASDAQ:AGEN) after the company began collaborations with Merck and Incyte for the discovery and development of …